Best Overall Response baseline to measured progressive disease (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death or up to 24 months after randomization) [clinicaltrials_resource:574737b21e38d3d87420c7dd7df1e2f9]

Best Overall Response baseline to measured progressive disease (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death or up to 24 months after randomization) [clinicaltrials_resource:574737b21e38d3d87420c7dd7df1e2f9]

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:574737b21e38d3d87420c7dd7df1e2f9
clinicaltrials:NCT00191854
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Best Overall Response baseline to measured progressive disease (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death or up to 24 months after randomization) [clinicaltrials_resource:574737b21e38d3d87420c7dd7df1e2f9]

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:574737b21e38d3d87420c7dd7df1e2f9
Bio2RDF identifier
574737b21e38d3d87420c7dd7df1e2f9
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:574737b21e38d3d87420c7dd7df1e2f9
measure [clinicaltrials_vocabulary:measure]
time frame [clinicaltrials_vocabulary:time-frame]
baseline to measured progressi ...... 24 months after randomization)
description
Response using Response Evalua ...... at do not meet above criteria.
identifier
clinicaltrials_resource:574737b21e38d3d87420c7dd7df1e2f9
title
Best Overall Response baseline ...... 24 months after randomization)
@en
inDataset
type
label
Best Overall Response baseline ...... 737b21e38d3d87420c7dd7df1e2f9]
@en